Get the Stockscreener App
10.84
1.90%
-0.21
After Hours:
10.84
Bioventus Inc stock is traded at $10.84, with a volume of 161.49K.
It is down -1.90% in the last 24 hours and up +10.27% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$11.05
Open:
$11.08
24h Volume:
161.49K
Relative Volume:
0.46
Market Cap:
$708.59M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-18.07
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
+1.78%
1M Performance:
+10.27%
6M Performance:
+33.99%
1Y Performance:
+137.72%
1-Day Range:
$10.79
$11.10
1-Week Range:
$10.35
$11.15
52-Week Range:
$3.90
$14.38
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
10.84 | 708.59M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
With 32% ownership, Bioventus Inc. (NASDAQ:BVS) has piqued the interest of institutional investors - Yahoo Finance
Learn to Evaluate (BVS) using the Charts - Stock Traders Daily
JPMorgan Chase & Co. Increases Holdings in Bioventus Inc. (NYSE:BVS) - MarketBeat
JPMorgan Chase & Co. Raises Position in Bioventus Inc. (NYSE:BVS) - Defense World
How to Take Advantage of moves in (BVS) - Stock Traders Daily
Barclays PLC Purchases 9,854 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet - MSN
Reed Smith represents Bioventus on its sale of Advanced Rehabilitation to Accelmed Partners - Reed Smith LLP
Bioventus CEO Robert Claypoole sells $261,952 in stock By Investing.com - Investing.com Nigeria
Robert E. Claypoole Sells 28,786 Shares of Bioventus Inc. (NYSE:BVS) Stock - MarketBeat
Bioventus CEO Robert Claypoole sells $261,952 in stock - Investing.com
Where are the Opportunities in (BVS) - Stock Traders Daily
Bioventus CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Principal Financial Group Inc. Takes Position in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus Inc. (NYSE:BVS) Shares Acquired by Jane Street Group LLC - Defense World
Bioventus (NYSE:BVS) Trading Down 5.9%Here's Why - MarketBeat
Bioventus: Amply Rewarded For Recent Progress (NASDAQ:BVS) - Seeking Alpha
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business - MSN
Bioventus completes divestiture of its Advanced Rehabilitation business - Yahoo Finance
Bioventus stock Buy rating reaffirmed, focus shifts to Ultrasonics and international growth - Investing.com India
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - The Manila Times
Bioventus Completes $20M Advanced Rehabilitation Business Sale to Accelmed Partners - StockTitan
Bioventus Inc. (NYSE:BVS) Shares Acquired by Barclays PLC - Defense World
Bioventus Inc. (NYSE:BVS) Shares Purchased by Geode Capital Management LLC - Defense World
Franklin Resources Inc. Takes $1.01 Million Position in Bioventus Inc. (NYSE:BVS) - Defense World
Franklin Resources Inc. Makes New Investment in Bioventus Inc. (NYSE:BVS) - MarketBeat
Bioventus Inc. (NYSE:BVS) Stock Position Lifted by State Street Corp - MarketBeat
State Street Corp Has $8.08 Million Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus SVP Anthony D'Adamio sells shares worth $61,579 By Investing.com - Investing.com Australia
Bioventus CFO Mark Leonard sells $113,018 in stock By Investing.com - Investing.com Australia
Bioventus CFO Mark Leonard sells $113,018 in stock - Investing.com India
Bioventus SVP Katrina Church sells $26,693 in stock By Investing.com - Investing.com Canada
Katrina J. Church Sells 2,535 Shares of Bioventus Inc. (NYSE:BVS) Stock - MarketBeat
Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells $113,018.49 in Stock - MarketBeat
Bioventus SVP Anthony D’Adamio sells shares worth $61,579 By Investing.com - Investing.com Nigeria
Bioventus SVP Anthony D'Adamio sells shares worth $61,579 - Investing.com India
Bioventus SVP Katrina Church sells $26,693 in stock - Investing.com
Shareholder lawsuit ends with $15 million settlement - The Business Journals
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? - MSN
Medical Device Investors Get Final OK On $15M Deal - Law360
Bioventus Investors Get $15 Million Med Rebate Deal Approved - Bloomberg Law
Bioventus (NYSE:BVS) Upgraded to “Neutral” at JPMorgan Chase & Co. - Defense World
JP Morgan Upgrades Bioventus (BVS) - MSN
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus (NYSE:BVS) Upgraded to Neutral at JPMorgan Chase & Co. - MarketBeat
Fmr LLC Acquires 166,014 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
Fmr LLC Raises Position in Bioventus Inc. (NYSE:BVS) - MarketBeat
Bioventus Inc. (NYSE:BVS) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Purchases 109,359 Shares of Bioventus Inc. (NYSE:BVS) - MarketBeat
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):